Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression

Molecular and Cellular Biology

Volumn 20, Issue 13, 2000, Pages 4580-4590

  Besson, Arnaud ^a   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN P21;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; ENZYME ACTIVITY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY;

CELL CYCLE; CELL DIVISION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME ACTIVATION; GLIOMA; HUMANS; ISOENZYMES; OLIGONUCLEOTIDES, ANTISENSE; PHORBOL ESTERS; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN KINASE C-EPSILON; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034045930     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.13.4580-4590.2000     Document Type: Article

References (53)

1. Ahmad, S., T. Mineta, R. L. Martuza, and R. I. Glazer. 1994. Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35:904-909.
2. Arita, Y., P. Buffolino, and D. L. Coppock. 1998. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity. Exp. Cell Res. 242:381-390.
3. Baltuch, G. H., G. Shenouda, A. Langleben, and J. H. Villemure. 1993. High dose tamoxifen in the treatment of recurrent high-grade glioma: a report of clinical stabilization and tumor regression. Can. J. Neurol. Sci. 20:168-170.
4. Baltuch, G. H., N. P. Dooley, W. T. Couldwell, and V. W. Yong. 1993. Staurosporine differentially inhibits glioma versus non-glioma cell lines. J. Neurooncol. 16:141-147.
5. Baltuch, G. H., N. P. Dooley, J.-G. Villemure, and V. W. Yong. 1995. Protein kinase C and growth regulation of malignant gliomas. Can. J. Neurol. Sci. 22: 264-271.
6. Begemann, M., S. A. Kashimawo, Y. J. A. Choi, et al. 1996. Inhibition of the growth of glioblastomas by CPG41251, an inhibitor of protein kinase C, and by phorbol ester tumor promoter. Clin. Cancer Res. 2:1017-1030.
7. Burns, K. L., K. Ueki, S. L. Jhung, J. Koh, and D. N. Louis. 1998. Molecular genetics correlates of p16, CDK4, and Rb immunochemistry in glioblastomas. J. Neuropathol. Exp. Neurol. 57:122-130.
8. Cheng, M., P. Olivier, J. A. Dielh, M. Fero, M. F. Roussel, J. M. Roberts, and C. J. Sherr. 1999. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
9. Costello, J. F., C. Plass, W. Arap, V. M. Chapman, W. A. Held, M. S. Berger, H. J. S. Huang, and W. K. Cavenee. 1997. Cyclin dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 57:1250-1254.
10. Couldwell, W. T., J. P. Antel, and V. W. Yong. 1992. Protein kinase C activity correlates with the growth rate of malignant gliomas. II. Effect of glioma mitogens and modulators of PKC. Neurosurgery 31:717-724.
11. Couldwell, W. T., D. R. Hinton, A. A. Surnock, C. M. DeGiorgio, L. P. Weiner, M. L. J. Apuzzo, L. Masri, and M. H. Weiss. 1996. Treatment of recurrent malignant gliomas with chronic oral high dose tamoxifen. Clin. Cancer Res. 2:619-622.
12. Dean, N., R. McKay, L. Miraglia, R. Howard, S. Cooper, J. Giddings, P. Nicklin, L. Meister, R. Ziel, T. Geiger, M. Muller, and D. Fabbro. 1996. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C alpha expression. Cancer Res. 56:3499-3507.
13. Delphin, C., and J. Baudier. 1994. The protein kinase C activator, phorbol ester, cooperates with wild type p53 species in ras transformed embryo fibroblasts growth arrest. J. Biol. Chem. 269:29579-29587.
14. Dirks, P. B., S. L. Hubbard, M. Murakami, and J. T. Rutka. 1997. Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J. Neuropathol. Exp. Neurol. 56:291-300.
15. Estanyol, J. M., M. Jaumont, O. Casanovas, A. Rodriguez-Vilarrupla, N. Agell, and O. Bachs. 1999. The protein SET regulates the inhibitory effect of p21/Cip1 on cyclin-E-cyclin dependent kinase-2 activity. J. Biol. Chem. 274: 33161-33165.
16. Fishman, D. D., S. Segal, and E. Livneh. 1998. The role of protein kinase C in G1 and G2/M phases of the cell cycle. Int. J. Oncol. 12:181-186.
17. Frey, M. R., M. L. Saxon, X. Zhao, A. Rollins, S. S. Evans, and J. D. Black. 1997. Protein kinase C mediated cell cycle arrest involves induction of p21Waf1/Cip1 and p27Kip1 and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J. Biol. Chem. 272:9424-9435.
18. Funk, J. O., S. Waga, J. B. Harry, E. Espling, B. Stillman, and D. A. Galloway. 1997. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:2090-2100.
19. Hamada, K., N. Takuwa, W. Zhou, M. Kumada, and Y. Takuwa. 1993. Protein kinase C inhibits the CAK-CDK2 cyclin dependent kinase cascade and G1/S cell cycle progression in human diploid fibroblasts. Biochim. Biophys. Acta 1310:149-156.
20. Hass, R., H. Gunji, M. Hirano, R. Weichselbaum, and D. Kufe. 1993. Phorbol ester induced monocytic differentiation is associated with G2 delay and down regulation of cdc25 expression. Cell Growth Differ. 4:159-156.
21. He, J., J. J. Olson, and C. D. James. 1995. Lack of p16INK4 or retinoblastoma protein (Rb), or amplification associated overexpression of CDK4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55:4833-4836.
22. Herman, J. G., J. Jen, A. Merlo, and S. B. Baylin. 1996. Hypermethylation associated inactivation indicates a tumor suppressor role for p15/INK4b1. Cancer Res. 56:722-727.
23. Hiyama, H., Iavarone A., and S. A. Reeves. 1998. Regulation of the CDK inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16:1513-1523.
24. Jaken, S. 1996. Protein kinase C isozymes and substrates. Curr. Opin. Cell Biol. 8:168-173.
25. Jones, D. L., R. M. Alani, and K. Munger. 1997. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11:2101-2111.
26. Jung, J. M., J. M. Bruner, S. Ruan, L. A. Langford, A. P. Kyritsis, T. Kobayashi, V. A. Levin, and W. Zhang. 1995b. Increased levels of p21/Waf1/ Cip1 in human brain tumors. Oncogene 11:2021-2028.
27. Kazanietz, M. G., L. B. Areces, A. Bahador, H. Mischak, J. Goodnight, J. F. Mushinski, and P. M. Blumberg. 1993. Characterization of ligand and substrate specificity for the calcium-dependent and calcium independent protein kinase C isozymes. Mol. Pharmacol. 44:298-307.
28. Korkolopoulou, P., K. Kouzelis, P. Christodoulou, A. Papanikolaou, and E. Thomas-Tsagli. 1998. Expression of retinoblastoma gene product and p21/ Waf1/Cip1 protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol. 95:617-624.
29. Kosaka, C., T. Sasaguri, A. Ishida, and J. Ogata. 1996. Cell cycle arrest in G2 phase induced by phorbol ester and diacylglycerol in vascular endothelial cells. Am. J. Physiol. 270:C170-C178.
30. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
31. Li, S., T. K. MacLachlan, A. De Luca, P. P. Claudio, G. Condorelli, and A. Giordano. 1995. The cdc-2 related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res. 55:3992-3995.
32. Livneh, E., T. Shimon, E. Bechor, Y. Doki, I. Schieren, and I. B. Weinstein. 1996. Linking protein kinase C to the cell cycle: ectopic expression of PKC eta in N1H-3T3 cells alters the expression of cyclins and CDK inhibitors and induces adipogenesis. Oncogene 12:1545-1555.
33. Livneh, E., and D. D. Fishman. 1997. Linking protein kinase C to cell cycle control. Eur. J. Biochem. 248:1-9.
34. Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9: 935-944.
35. Mann, D. J., T. Higgins, N. C. Jones, and E. Rozengurt. 1997. Differential control of cyclins D1 and D3 and the CDK inhibitor p27/Kip1 by diverse signaling pathways in Swiss 3T3 cells. Oncogene 14:1759-1766.
36. Mantel, C., Z. Luo, J. Canfield, S. Braun, C. Deng, and H. E. Broxmeyer. 1996. Involvement of p21Cip1 and p27Kip1 in the molecular mechanisms of Steel Factor induced proliferative synergy in vitro and of p21Cip1 in the maintenance of stem/progenitor cells in vivo. Blood 88:3710-3719.
37. Mastronardi, L., F. Puzzilli, W. T. Couldwell, J. O. Farah, and P. Lunardi. 1998. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. J. Neurooncol. 38:59-68.
38. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
39. Mellor, H. and P. J. Parker. 1998. The extended protein kinase C super-family. Biochem. J. 332:281-292.
40. Michieli, P., M. Chedid, D. Lin, J. H. Pierce, W. E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res. 54:3391-3395.
41. Newton, A. C. 1997. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9: 161-167.
42. Nourse, J., E. Firpo, W. M. Flanagan, S. Coats, K. Polyak, M. H. Lee, J. Massague, G. R. Crabtree, and J. M. Roberts. 1994. Interleukin-2 mediated elimination of the p27Kip1 cyclin dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573.
43. Pollack, I. F., and S. Kawecki. 1997. The effect of Calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J. Neurooncol. 31:255-266.
44. Ryves, W. J., A. T. Evans, A. R. Olivier, P. J. Parker, and F. J. Evans. 1991. Activation of the PKC isotypes alpha, beta 1, gamma, delta, and epsilon by phorbol esters of different biological activities. FEBS Lett. 288:5-9.
45. Sioud, M. and D. R. Sorensen. 1998. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat. Biotechnol. 16:556-561.
46. Sonoda, Y., T. Yoshimoto, and T. Sekiya. 1995. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11:2145-2149.
47. Srivenugopal, K. S., and F. Ali-Osman. 1996. Deletions and rearrangements inactivate the p16/INK4 gene in human glioma cells. Oncogene 12:2029-2034.
48. Thompson, L. J., and A. P. Fields. 1996. Beta2 protein kinase C is required for the G2/M transition of cell cycle. J. Biol. Chem. 271:15045-15053.
49. Yazaki, T., S. Ahmad, A. Chablavi, E. Zylber-Katz, N. M. Dean, S. D. Rabkin, R. L. Martuza, and R. I. Glazer. 1996. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50:236-242.
50. Yong, V. W., N. P. Dooley, and P. G. Noble. 1994. Protein kinase C in cultured adult human oligodendrocytes: a potential role for isoform alpha as a mediator of process outgrowth. J. Neurosci. Res. 39:83-96.
51. Zeng, Y.-X., and W. S. El-Deiry. 1996. Regulation of P21/Waf1/Cip1 expression by p53 independent mechanisms. Oncogene 12:1557-1564.
52. Zezula, J., V. Sexl, C. Hutter, A. Karel, W. Schutz, and M. Freissmuth. 1997. The cyclin-dependent kinase inhibitor p21cip1 mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells. J. Biol. Chem. 272:29967-29974.
53. Zhang, H., G. H. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.